Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Trace amounts of microbe-killing molecules predict chronic granulomatous disease survival

30.12.2010
NIH study could improve care for chronic granulomatous disease

Investigators at the National Institutes of Health have observed that the survival rate of people with a rare immunodeficiency disease called chronic granulomatous disease (CGD) is greatly improved when even very low levels of microbe-killing molecules are present. Because production of these molecules, made by an enzyme called NADPH oxidase, can be predicted from genetic analysis, a patient's risk for severe CGD could be assessed very early in life, allowing for more personalized treatment, say the researchers.

The study was conducted at the NIH Clinical Center and led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and their associated contract labs at SAIC-Frederick Inc. The study is available online in the New England Journal of Medicine.

"Advances in treatment of CGD have made it possible for people with this once-fatal disease of early childhood to survive into adulthood; however, the disease remains difficult to manage," says NIAID Director Anthony S. Fauci, M.D. "Having a marker to help predict disease prognosis will enable physicians to recommend treatment options that are more tailored to the needs of individual patients."

People with CGD have increased susceptibility to infections caused by certain bacteria, such as Staphylococcus aureus, and fungi, such as Aspergillus. They can have abscesses in the lungs, liver, spleen, bones or skin. Those with severe disease also can have tissue masses, called granulomas, which can obstruct the bowel or urinary tract. CGD affects an estimated 1,200 people in the United States and approximately 25,000 people worldwide.

The disease is caused by inherited mutations in any one of five different genes required by immune cells to make the NADPH oxidase enzyme, which in turn makes superoxide, an oxygen-derived molecule that immune cells use to destroy harmful bacteria and fungi. All CGD patients have impaired superoxide production. Some make a little superoxide, while others make none. The research team found that the level of superoxide production was linked to the type of mutation in the NADPH oxidase gene, and that the more superoxide a patient with CGD can make, the less severe the disease and the greater the life expectancy.

Until now, the severity of CGD has been linked only to how people inherit the NADPH oxidase gene mutation. If people inherit the mutation as an autosomal recessive trait, meaning that two copies of the abnormal gene, one from each parent, are present, the disease has generally been less severe than in those who inherit the mutation as an X-linked trait, meaning that the abnormal gene is located on the female sex chromosome. The majority of people with CGD inherit the mutation as an X-linked trait.

For their study, the NIH team tested the level of superoxide production by immune cells isolated from blood samples taken from 287 people with CGD, aged 1 to 64 years old, compared with superoxide production in healthy people. Some tests dated back to 1993, though patients and families affected by CGD have come to the NIH Clinical Center for treatment since the 1970s.

The NIH researchers used methods that could detect even trace amounts of superoxide, and grouped people with CGD based on the amount of superoxide made by the immune cells. The patients who produced the highest levels of superoxide had the highest survival rates, whereas those who produced the lowest levels of superoxide had the lowest survival rates.

"By precisely measuring superoxide production, we observed that even tiny residual amounts, at levels below what doctors paid attention to in the past, had a significant impact on patient survival," says John Gallin, M.D., director of the NIH Clinical Center, chief of the Clinical Pathophysiology Section of the NIAID Laboratory of Host Defenses, and senior author on the paper.

Treatment of CGD consists of lifelong antibiotics and antifungal medications. Some people also receive injections with interferon-gamma, a protein that can stimulate the immune cells to fight infections. For people with the most severe forms of CGD, bone marrow transplantation is a treatment option, but it carries potential complications that can make patients and their families reluctant to elect this therapy.

Based on the research team's observations, doctors should be able to use DNA gene-typing results to help identify those patients who are candidates for more aggressive treatments, including possible bone marrow transplantation. Bone marrow transplantation replaces the immune cells of people with CGD, which produce no or reduced amounts of microbe-killing superoxide, with healthy immune cells. In addition, therapies designed to promote NADPH oxidase function might reduce CGD severity. Therapies exist to stimulate NADPH oxidase but none are used to treat CGD.

"This study is a great example of the special strengths of the Clinical Center," comments Dr. Gallin. "We have worked for over three decades with patients with CGD, which at one time was almost entirely fatal, and have seen vast improvements in care and treatment. This work now gives us another tool to help individuals fight this disease."

Additional support for this research was provided by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute, also components of NIH, and SAIC-Frederick Inc.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

NIDDK, a component of the NIH, conducts and supports research in diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe, and disabling conditions affecting Americans. For more information about NIDDK and its programs, see www.niddk.nih.gov.

NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Reference: DB Kuhns et al. Residual NADPH oxidase and survival in chronic granulomatous disease. New England Journal of Medicine. DOI: 10.1056/NEJMoa1007097 (2010).

Julie Wu | EurekAlert!
Further information:
http://www.niaid.nih.gov

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>